The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Combining SBRT with chemotherapy and KRAS inhibitors in pancreatic cancer
Andrew Oar, MBBS, Icon Cancer Centre, Southport, Australia, highlights the significance of the AGITG MASTERPLAN trial (ACTRN12619000409178), where there is great potential in combining stereotactic body radiation therapy (SBRT) with chemotherapy. There is also promise of combining SBRT with KRAS inhibitors in earlier stages of disease. The interplay between SBRT and KRAS inhibitors could lead to improved outcomes in patients with metastatic pancreatic cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
